Clinical study of Compound Huonaoshu Capsules combined with rivastigmine in treatment of Alzheimer's disease
Objective To investigate the therapeutic effect of Compound Huonaoshu Capsules combined with Rivastigmine Hydrogen Tartrate Capsules in treatment of Alzheimer's disease. Methods A total of 96 patients with Alzheimer's disease treated in Tangdu Hospital of Air Force Military Medical University from January 2020 to February 2023 were selected and divided into control group and treatment group by random number table method,with 48 patients in each group. Patients in the control group were po administered with Rivastigmine Hydrogen Tartrate Capsules,the initial dosage was 3 mg/d,taken twice at breakfast and dinner. After 4 weeks,the dosage could be adjusted to 6 mg/d if no intolerance occurs. If the tolerance was good,the dosage could be continued to the maximum tolerated dosage,but the daily dosage should not exceed 12 mg. Patients in treatment group were po administered with Compound Huonaoshu Capsules on the basis of the control group,3 grain/time,twice daily. Both groups were treated continuously for 6 months. The clinical effects of the two groups were observed,and the scores of Alzheimer's Disease Assessment Scale-Cognitive Scale (ADAS-cog),Daily Living Ability Assessment Scale (ADL),TCM symptom score and serum malondialdehyde and reduced glutathione (GSH) before and after treatment were compared. Results After treatment,the total effective rate of treatment group was 93.75％,which was higher than that of control group 79.17％ (P<0.05). After treatment,the ADAS-cog scores and ADL scores in both groups were lower than before treatment (P<0.05). After treatment,ADAS-cog scores and ADL scores in the treatment group were lower than those in the control group (P<0.05). After treatment,the scores of mental fatigue,mental impairment and heart palpitation were lower than before treatment (P<0.05). After treatment,the symptom score of the treatment group was lower than that of the control group (P<0.05). After treatment,serum malondialdehyde level was lower than before treatment,but serum GSH level was higher than before treatment (P<0.05). After treatment,the serum malondialdehyde level in the treatment group was lower than that in the control group,and the serum GSH level was higher than that in the control group (P<0.05). Conclusion Compound Huonaoshu Capsules combined with Rivastigmine Hydrogen Tartrate Capsules can obtain satisfactory curative effect in treatment of Alzheimer's disease,and can significantly improve the symptoms of Chinese medicine,cognitive function and self-care ability of patients,which can reduce the level of oxidative stress with good safety.
NETL
NSTL
万方数据
